N/A
Completed N=1,294
Educational Intervention to Minimize Disparities in Humanpapillomavirus Vaccination
HPV Vaccination Status
Source: ClinicalTrials.gov NCT02145156 ↗
Enrolled (actual)
1,294
Serious AEs
0.0%
Results posted
Aug 2016
Primary outcomePrimary: Number of Young Adults Who Received Any Dose of the HPV Vaccine During the Study Period — 8; 9; 3 participants — p=.36
Summary
The purpose of this study is to evaluate an innovative approach to improving HPV vaccination among the Hispanic population. The clinical objectives/aims of this HPV educational intervention project are to determine:
1. The number of young adults and adolescents in each arm who received any dose of the HPV vaccine during the study period,
2. The number of young adults and adolescents in each arm who initiated the HPV vaccine series during the study period,
3. The number of young adults and adolescents in each arm who initiated but did not complete the HPV vaccine series during the study period,
4. The number of young adults and adolescents in each arm, among all eligible, who completed the HPV vaccine series during the study period,
5. The number of young adults and adolescents in each arm who completed the HPV vaccine series during the study period, among those who initiated the series at study start, and
6. The number of young adults and adolescents in each arm who completed the HPV vaccine series among those who initiated the series during the study period.
The implementation of this educational intervention in clinic waiting rooms is intended to assist primary care providers in communicating HPV vaccine awareness and education to parents and patients in a culturally tailored format.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Young Adults Who Received Any Dose of the HPV Vaccine During the Study Period |
8; 9; 3 | .36 |
| PRIMARY Number of Young Adults Who Initiated the HPV Vaccine Series During the Study Period |
7; 4; 3 | 0.35 |
| PRIMARY Number of Young Adults Who Initiated But Did Not Complete the HPV Vaccine Series During the Study Period |
9; 12; 6 | 0.37 |
| PRIMARY Number of Young Adults, Among All Eligible, Who Completed the HPV Vaccine Series During the Study Period |
1; 4; 2 | 0.59 |
| PRIMARY Number of Young Adults Who Completed the HPV Vaccine Series During the Study Period, Among Those Who Initiated the Series at Study Start |
0; 4; 0 | 0.16 |
| PRIMARY Number of Young Adults Who Completed the HPV Vaccine Series Among Those Who Initiated the Series During the Study Period |
2; 0; 5 | 0.37 |
| PRIMARY Number of Adolescents Who Received Any Dose of the HPV Vaccine During the Study Period |
124; 122; 121 | 0.87 |
| PRIMARY Number of Adolescents Who Initiated the HPV Vaccine Series During the Study Period |
74; 73; 75 | 0.70 |
| PRIMARY Number of Adolescents Who Initiated But Did Not Complete the HPV Vaccine Series During the Study Period |
79; 93; 89 | 0.38 |
| PRIMARY Number of Adolescents, Among All Eligible, Who Completed the HPV Vaccine Series During the Study Period |
54; 39; 48 | 0.39 |
| PRIMARY Number of Adolescents Who Completed the HPV Vaccine Series During the Study Period, Among Those Who Initiated the Series at Study Start |
59; 41; 55 | 0.09 |
| PRIMARY Number of Adolescents Who Completed the HPV Vaccine Series Among Those Who Initiated the Series During the Study Period |
24; 13; 36 | 0.38 |
Eligibility Criteria
Inclusion Criteria
- Parents of an adolescent between the ages of 9-17; OR a young adult patient between the ages of 18-26;
- Adolescent/young adult has not yet received all three doses of the HPV vaccine.
- Parent/young adult can read and converse in either English or Spanish
Exclusion Criteria
- Age <18,
- Prisoners
- Decisionally challenged subjects
- Those who cannot read and converse in either English or Spanish
- Those who have received all 3 doses of the HPV vaccine
Data sourced from ClinicalTrials.gov (NCT02145156). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.